OncoMatch/Clinical Trials/NCT06184321

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

Is NCT06184321 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Alteplase for hematopoietic and lymphoid cell neoplasm.

Early Phase 1RecruitingM.D. Anderson Cancer CenterNCT06184321Data as of May 2026

Treatment: Alteplase — This study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. Alteplase helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. Alteplase may help to control symptoms of breathlessness.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Non-Hodgkin Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Chronic Lymphocytic Leukemia

Tumor Agnostic

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

M D Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify